2007
DOI: 10.1159/000099465
|View full text |Cite
|
Sign up to set email alerts
|

Antagonism of IL-4 Signaling by a Phosphodiesterase-4 Inhibitor, Rolipram, in Human T Cells

Abstract: Background: Phosphodiesterase (PDE4) inhibitors prevent breakdown of cAMP and affect the increase in cellular levels of cAMP, which is known to regulate immune cell functions. Because IL-4 plays a causal role in the pathogenesis of allergic disorders, we were interested to study the modulatory mechanisms of a PDE4 inhibitor, rolipram, in IL-4-mediated signaling in T cells. Methods: Human peripheral T cells were stimulated with IL-4 in combination with rolipram, and RT-PCR was performed using primers specific f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2008
2008
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 39 publications
(24 reference statements)
0
1
0
Order By: Relevance
“…[145,146140,141] Inhibitors of PDE have shown clinical benefit when used topically in AD patients. [148143] An open label study with Apremilast, a novel oral PDE4 inhibitor that is currently in phase 2 clinical trials for psoriasis, was given to 16 adult patients with moderate to severe AD, in two cohorts of 6 patients receiving a lower dose of 20 mg twice daily and 10 on the higher dose of 30 mg twice daily. [149144] The clinical responses seen at 6 months showed a reduction of approx 50% in the EASI score in the cohort obtaining the highest dosing.…”
Section: Emerging Therapeutics (Table 1)mentioning
confidence: 99%
“…[145,146140,141] Inhibitors of PDE have shown clinical benefit when used topically in AD patients. [148143] An open label study with Apremilast, a novel oral PDE4 inhibitor that is currently in phase 2 clinical trials for psoriasis, was given to 16 adult patients with moderate to severe AD, in two cohorts of 6 patients receiving a lower dose of 20 mg twice daily and 10 on the higher dose of 30 mg twice daily. [149144] The clinical responses seen at 6 months showed a reduction of approx 50% in the EASI score in the cohort obtaining the highest dosing.…”
Section: Emerging Therapeutics (Table 1)mentioning
confidence: 99%